Treatment of First-Episode Schizophrenia in a Young Woman | Psychiatry and Behavioral Health | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Treatment of First-Episode Schizophrenia in a Young Woman

Educational Objective
Based on this clinical scenario and the accompanying image, understand how to arrive at a correct diagnosis.
1 Credit CME

Please finish quiz first before checking answer.

You answered correctly!

Read the answer below and download your certificate.

You answered incorrectly.

Read the discussion below and retake the quiz.

Survey Complete!

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Oliver D. Howes, MD, PhD, Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, Kings College London, De Crespigny Park, PO Box 67, London SE5 8AF, United Kingdom (oliver.howes@kcl.ac.uk).

Published Online: October 30, 2019. doi:10.1001/jamapsychiatry.2019.3369

Correction: This article was corrected on January 15, 2020, to fix a quiz answer and text in the Discussion and Patient Outcome sections.

Conflict of Interest Disclosures: Dr Reis Marques reported personal fees from Lundbeck, Janssen, Astellas, and Angelini and grants from Medical Research Council of the United Kingdom during the conduct of the study. Dr Howes reported grants, personal fees, and nonfinancial support from Angelini, AstraZeneca, Autifony, Biogen, Eli Lilly, Heptares, Janssen, Lundbeck, Lyden-Delta, Otsuka, Sunovion, Rand, Recordati, and Roche outside the submitted work. No other disclosures were reported.

Additional Contributions: We thank the patient for granting permission to publish this information.

References
1.
Leucht  S, Cipriani  A, Spineli  L,  et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.  Lancet. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3PubMedGoogle ScholarCrossref
2.
Huhn  M, Nikolakopoulou  A, Schneider-Thoma  J,  et al.  Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.  Lancet. 2019;6736(19):1-13. doi:10.1016/S0140-6736(19)31135-3PubMedGoogle Scholar
3.
Leucht  S, Tardy  M, Komossa  K,  et al.  Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.  Lancet. 2012;379(9831):2063-2071. doi:10.1016/S0140-6736(12)60239-6PubMedGoogle ScholarCrossref
4.
Ananth  J, Kolli  S, Gunatilake  S, Brown  S.  Atypical antipsychotic drugs, diabetes and ethnicity.  Expert Opin Drug Saf. 2005;4(6):1111-1124. doi:10.1517/14740338.4.6.1111PubMedGoogle ScholarCrossref
5.
Pillinger  T, Beck  K, Gobjila  C, Donocik  JG, Jauhar  S, Howes  OD.  Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis.  JAMA Psychiatry. 2017;74(3):261-269. doi:10.1001/jamapsychiatry.2016.3803PubMedGoogle ScholarCrossref
6.
Agid  O, Arenovich  T, Sajeev  G,  et al.  An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.  J Clin Psychiatry. 2011;72(11):1439-1444. doi:10.4088/JCP.09m05785yelPubMedGoogle ScholarCrossref
7.
Subotnik  KL, Casaus  LR, Ventura  J,  et al.  Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial.  JAMA Psychiatry. 2015;72(8):822-829. doi:10.1001/jamapsychiatry.2015.0270PubMedGoogle ScholarCrossref
8.
Taylor  D, Paton  C, Kapur  S.  The Maudsley Prescribing Guidelines in Psychiatry, 12th Edition. London, United Kingdom: John Wiley & Sons; 2015.
9.
Fusar-Poli  P, McGorry  PD, Kane  JM.  Improving outcomes of first-episode psychosis: an overview.  World Psychiatry. 2017;16(3):251-265. doi:10.1002/wps.20446PubMedGoogle ScholarCrossref
10.
Bighelli  I, Salanti  G, Huhn  M,  et al.  Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis.  World Psychiatry. 2018;17(3):316-329. doi:10.1002/wps.20577PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close